Chemomab Therapeutics Stock Forecast - Naive Prediction
| CMMB Stock | USD 0.67 0.01 1.52% |
The Naive Prediction forecasted value of Chemomab Therapeutics Ltd on the next trading day is expected to be 0.64 with a mean absolute deviation of 0.03 and the sum of the absolute errors of 1.78. Chemomab Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Chemomab Therapeutics stock prices and determine the direction of Chemomab Therapeutics Ltd's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Chemomab Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns. Although Chemomab Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Chemomab Therapeutics' systematic risk associated with finding meaningful patterns of Chemomab Therapeutics fundamentals over time.
Check out Historical Fundamental Analysis of Chemomab Therapeutics to cross-verify your projections. Chemomab |
Most investors in Chemomab Therapeutics cannot accurately predict what will happen the next trading day because, historically, stock markets tend to be unpredictable and even illogical. Modeling turbulent structures requires applying different statistical methods, techniques, and algorithms to find hidden data structures or patterns within the Chemomab Therapeutics' time series price data and predict how it will affect future prices. One of these methodologies is forecasting, which interprets Chemomab Therapeutics' price structures and extracts relationships that further increase the generated results' accuracy.
A naive forecasting model for Chemomab Therapeutics is a special case of the moving average forecasting where the number of periods used for smoothing is one. Therefore, the forecast of Chemomab Therapeutics Ltd value for a given trading day is simply the observed value for the previous period. Due to the simplistic nature of the naive forecasting model, it can only be used to forecast up to one period. Chemomab Therapeutics Naive Prediction Price Forecast For the 25th of April
Given 90 days horizon, the Naive Prediction forecasted value of Chemomab Therapeutics Ltd on the next trading day is expected to be 0.64 with a mean absolute deviation of 0.03, mean absolute percentage error of 0, and the sum of the absolute errors of 1.78.Please note that although there have been many attempts to predict Chemomab Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Chemomab Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Chemomab Therapeutics Stock Forecast Pattern
| Backtest Chemomab Therapeutics | Chemomab Therapeutics Price Prediction | Buy or Sell Advice |
Chemomab Therapeutics Forecasted Value
In the context of forecasting Chemomab Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Chemomab Therapeutics' downside and upside margins for the forecasting period are 0.01 and 5.66, respectively. We have considered Chemomab Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Chemomab Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Chemomab Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 111.5324 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0291 |
| MAPE | Mean absolute percentage error | 0.041 |
| SAE | Sum of the absolute errors | 1.7766 |
Predictive Modules for Chemomab Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Chemomab Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Chemomab Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Other Forecasting Options for Chemomab Therapeutics
For every potential investor in Chemomab, whether a beginner or expert, Chemomab Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Chemomab Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Chemomab. Basic forecasting techniques help filter out the noise by identifying Chemomab Therapeutics' price trends.View Chemomab Therapeutics Related Equities
| Risk & Return | Correlation |
Chemomab Therapeutics Technical and Predictive Analytics
The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Chemomab Therapeutics' price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Chemomab Therapeutics' current price.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Chemomab Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Chemomab Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Chemomab Therapeutics shares will generate the highest return on investment. By undertsting and applying Chemomab Therapeutics stock market strength indicators, traders can identify Chemomab Therapeutics Ltd entry and exit signals to maximize returns.
Chemomab Therapeutics Risk Indicators
The analysis of Chemomab Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Chemomab Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting chemomab stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.47 | |||
| Semi Deviation | 3.63 | |||
| Standard Deviation | 4.93 | |||
| Variance | 24.27 | |||
| Downside Variance | 22.62 | |||
| Semi Variance | 13.18 | |||
| Expected Short fall | (4.74) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Chemomab Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Chemomab Therapeutics' short interest history, or implied volatility extrapolated from Chemomab Therapeutics options trading.
Pair Trading with Chemomab Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemomab Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemomab Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Chemomab Stock
| 0.74 | VKTX | Viking Therapeutics Earnings Call Today | PairCorr |
| 0.76 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
Moving against Chemomab Stock
| 0.48 | GILD | Gilead Sciences Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Chemomab Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chemomab Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chemomab Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chemomab Therapeutics Ltd to buy it.
The correlation of Chemomab Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chemomab Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chemomab Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chemomab Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Historical Fundamental Analysis of Chemomab Therapeutics to cross-verify your projections. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Chemomab Stock analysis
When running Chemomab Therapeutics' price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Chemomab Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.06) | Return On Assets (0.49) | Return On Equity (0.91) |
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.